ADAP – adaptimmune therapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Adaptimmune Therapeutics plc (NASDAQ: ADAP) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise [Yahoo! Finance]
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications [Yahoo! Finance]
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications [Yahoo! Finance]
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $3.15 price target on the stock.
Form 8-K Adaptimmune Therapeutics For: Jun 11
Form 8-K Adaptimmune Therapeutics For: May 30
Form 10-Q Adaptimmune Therapeutics For: Mar 31
Form 8-K Adaptimmune Therapeutics For: May 15
Form 8-K Adaptimmune Therapeutics For: May 14
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.